Free Shipping for orders over $49 within the U.S.

Clinical Trails

June 09, 2020

Clinical Trails by pubmed.gov 

A systematic review and meta-analysis of randomized controlled trials found low quality evidence implying Dengzhan Xixin (Erigeron breviscapus) injection appeared to improve neurological function in patients with acute ischemic stroke. Li 2017

Meta-analysis of 39 randomized controlled trials showed that breviscapine injection had higher total efficiency and safety than E. breviscapus injection. Due to the low quality of the studies, these 2 medicines should be comprehensively compared in high-quality clinical trials. [Article in Chinese] Zhang 2017

In a randomized, open-label, single-center, double-arm, dose-escalation study, an intravenous infusion of Erigerontis hydroxybenzenes injection, a phenolic compound-enriched product extracted from E. breviscapus, was generally tolerated in in healthy volunteers. Pharmacokinetics was also studied. Ju 2015

A randomized controlled trial (n=40) found that Erigeron breviscapus extract may have a partial protective effect on the visual field of glaucoma patients with controlled intraocular pressure. Zhong 2010